68 related articles for article (PubMed ID: 8978801)
1. [Etoposide 21 therapy for malignant lymphoma].
Masaoka T
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1936-40. PubMed ID: 8978801
[TBL] [Abstract][Full Text] [Related]
2. [Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
Yoshida T; Takagi T; Shimoyama M; Mikuni C; Suzuki K; Egami K; Furusawa S; Nomura T; Mori M; Sugimoto T
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2793-801. PubMed ID: 7993116
[TBL] [Abstract][Full Text] [Related]
3. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Noda K; Tanaka K; Ozaki M; Hirabayasi K; Hasegawa K; Nishiya I; Yakushiji M; Izumi R; Tomoda Y; Ogita Y; Sugimori H; Yamabe T; Kudo R; Yajima A; Terashima Y; Fujii S; Suzuoki Y; Okada H; Kono I; Ochiai K; Yamamoto T; Ikeda M; Umesaki N; Saito T; Niitani H
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2061-8. PubMed ID: 9838908
[TBL] [Abstract][Full Text] [Related]
4. [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
Tagawa S; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan No Rinsho; 1987 Jan; 33(1):1-7. PubMed ID: 3469424
[TBL] [Abstract][Full Text] [Related]
5. Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
Shaklai S; Bairey O; Blickstein D; Prokocimer M; Hadar H; Lahav M; Sulkes J; Shaklai M
Cancer; 1996 Jun; 77(11):2313-7. PubMed ID: 8635101
[TBL] [Abstract][Full Text] [Related]
6. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. [Late phase II study of MST-16 (sobuzoxane) efficacy for malignant lymphoma].
Masaoka T; Kageyama T; Tatsumi N; Akasaka K; Yonezawa T; Sugiyama H; Kitani T; Yasunaga K; Horiuchi A; Nakayama S
Gan To Kagaku Ryoho; 1992 Mar; 19(3):339-47. PubMed ID: 1543360
[TBL] [Abstract][Full Text] [Related]
11. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
12. [Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies].
Kuga T; Kohda K; Matsumoto S; Nakazawa O; Ezoe A; Nobuoka A; Mochizuki C; Niitsu Y; Watanabe N
Gan To Kagaku Ryoho; 1997 Feb; 24(3):315-21. PubMed ID: 9051134
[TBL] [Abstract][Full Text] [Related]
13. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
[TBL] [Abstract][Full Text] [Related]
14. [Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group].
Ikeda M; Noda K; Hiura M; Tamaya T; Ozaki M; Hatae M; Ozawa M; Yamabe T; Tanaka K; Izumi R; Okada H; Ogita Y; Hoshiai H
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2249-57. PubMed ID: 9881082
[TBL] [Abstract][Full Text] [Related]
15. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
16. [Late phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Yamada K; Ohno R; Oguri T; Kamiya O; Yokomaku S; Kobayashi M; Nishiwaki H; Tanaka M; Inagaki J; Mitomo Y
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2447-52. PubMed ID: 1952964
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
18. [Effect of daily administration of oral etoposide for non-small cell lung cancer treated with concurrent radiation therapy].
Ohnishi H; Okada J; Yamaguchi M; Ogata H; Hatano K; Takizawa Y; Imai Y; Hara R; Araki T
Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Jul; 57(8):510-4. PubMed ID: 9267140
[TBL] [Abstract][Full Text] [Related]
19. [ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].
Yoshida T; Nakanishi J; Ito K; Kobayashi K; Ohtake S; Nakamura S; Matsuda T; Nakagoshi T; Natori K; Nakamura E
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):984-9. PubMed ID: 3963862
[TBL] [Abstract][Full Text] [Related]
20. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
